Jasper Therapeutics(US:JSPR) Globenewswireยท2025-05-14 20:30Company Overview - Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing briquilimab, a novel antibody therapy targeting KIT to treat mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma [2] Product Development - Briquilimab is a targeted aglycosylated monoclonal antibody that inhibits the binding of stem cell factor to the cell-surface receptor KIT, leading to the depletion of mast cells through apoptosis, which addresses the inflammatory response in mast cell driven diseases [2] - The company is currently conducting clinical studies of briquilimab for patients with CSU, CIndU, or asthma, demonstrating efficacy and safety in previous trials [2] Investor Engagement - Jasper Therapeutics will participate in the RBC Capital Markets 2025 Global Healthcare Conference on May 21, 2025, and the Jefferies 2025 Global Healthcare Conference on June 5, 2025, with live webcasts available on their Investor Relations website [1]